In addition, the aberrant methylation profile of genes such as, DLX5, SOX30, CDH1, p15(INK4B) promoter, is significantly higher in AML and MDS-derived AML and could act as a predictive biomarker [17–21]. This evidence concerns the gene CDKN2B and acute myeloid leukemia.